American Society of Hematology

An updated meta-analysis from ASH 2019 is detailing the apparent risk of atrial fibrillation and major bleeding associated with ibrutinib use in patients with hematologic malignancies.

Investigators point out some of the reasons as to why there are less African Americans involved in AML clinical trials.

Timely identification of non-responders could reduce toxicities and costs, investigators wrote.

A new study presented at ASH 2019 is providing further evidence for the use of weight-adjusted rivaroxaban in children with venous thromboembolism.

A recent study from Penn Medicine presented at ASH 2019 has found mosunetuzumab could be an effective treatment for B-cell non-Hodgkin lymphoma refractory to CAR T therapy.

How do primary care physicians interact with specialists, and what is the current state of care?

During the annual ASH meeting, investigators issue new clinical development guidelines for sickle cell disease therapies.

Mohamad Mohty, MD, PhD, discusses the investigational therapy cytotoxic T lymphocytes (CTLs) therapy for the treatment of Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBVPTLD).

An early prophylaxis in combination with an assistant device like myPKFit can improve the outcomes of treatment.

This rare leukemia form may be treated with ruxolitinib, which appears to be well-tolerated by patients.

Patients with myeloproliferative neoplasms (MPN) with essential thrombocythemia (ET) or polycythemia vera (PV) were found to benefit from hydroxyurea therapy.

Patients with myeloid/lymphoid neoplasms enrolled in the phase 2 clinical trial demonstrated pemigatinib was generally well-tolerated.

Nizar Bahlis, MD, highlights the phase 3 POLLUX trial evaluating daratumumab plus lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma.

Among the highlights, significant and sustained increases in hemoglobin without transfusions stood out.

Lead investigator, John Leonard, MD, reviews the phase 3 AUGMENT trial investigating lenalidomide plus rituximab for the treatment of relapsed/refractory follicular lymphoma.

Models show that for every gram of hemoglobin increased per deciliter, the risks associated with hemolytic anemia decrease.

Jorge Cortes, MD, highlights the phase 3 QuANTUM-R trial results and explains their clinical implications for patients with FLT3-ITD-mutated relapsed/refractory acute myeloid leukemia (AML).

Patients’ daily bleed diaries helped investigators understand why some bleeds are treated, and some are not, as well as their causes.

Jasmine Zain, MD, recaps the current and upcoming treatments in T-cell lymphoma and highlights the key clinical trials playing a role in the rare disease.

The pediatrician discusses key differences between treating pediatric and adult patients with hemophagocytic lymphohistiocytosis (HLH) with the recently FDA-approved emapalumab.

The therapy attempts to restore fetal hemoglobin production.

Ravulizumab dosed every 8 weeks was noninferior to eculizumab given every 2 weeks, but the treatment did not achieve superiority.

Among the highlights observed in the data, the single-agent oral demonstrated significant improvement in progression-free survival (PFS).

Full results from the phase 3 MURANO trial showed a reduced risk in disease progression and 87.9% overall survival in relapsed/refractory chronic lymphocytic leukemia patients treated with venetoclax/rituximab.

Currently available anemia therapies only provide benefit for about half of patients with a lower-risk myelodysplastic syndromes (MDS)-related condition—and about one-quarter of such patients dependent on red blood cell transfusions.

Justin Taylor, MD, explains new and unique data that show cases in which a solid tumor can become a hematologic malignancy, or leukemia.

Males with myeloproliferative neoplasms (MPN) were found to have inferior survival compared to females in a well-defined, prospective, observational cohort.

The odds ratio of patients on the therapy reaching ≥33% RBC transfusion burden reduction was 5 times greater than those on placebo.

Long-term data shows familial haploidentical stem cell transplantation (HISCT) improves quality of life and neurocognition in sickle cell disease patients.

A new treatment option for deep vein thrombosis (DVT) and pulmonary embolism (PE) was recently introduced, but it looks like old habits die hard when it comes to prescriptions.